Autonomix medical, inc. announces u.s. patent granted covering the treatment of cancerous tumors and cancer related pain with company's proprietary catheter-based technology

Growing global patent portfolio to over 120 patents with 80 issued patents and over 40 pending patent applications previously completed preclinical study evaluating targeted nerve ablation demonstrated statistically significant reduction of metastases and statistically significant reduction in tumor mass the woodlands, tx, dec. 30, 2024 (globe newswire) -- autonomix medical, inc. (nasdaq: amix) (“autonomix” or the “company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the united states patent and trademark office (uspto) has issued u.s. patent 12,064,256 (‘256 patent) titled, systems and methods for treating cancer and/or augmenting organ function. the issued ‘256 patent covers technology including, but not limited to, systems, methods and devices for interventionally treating cancerous tumors and cancer related pain.
AMIX Ratings Summary
AMIX Quant Ranking